VIP Peptide Dosing Guide: Optimal Protocols

Overview

VIP is a research peptide discussed for its potential effects. This guide provides an educational overview of VIP dosing patterns based on published research and peptide community discussions, presented as a text-based dosage chart for discussion with a licensed healthcare provider. You can use our VIP dosage calculator → to plan protocol schedules and check reconstitution math — for educational purposes only.

What is VIP?

VIP is a peptide compound discussed in research contexts.

Key characteristics:

Mechanism:
Route: intranasal or subcutaneous
Legal status: Not FDA-approved — research only
Half-life: ~1-2 minutes
Category:

To calculate your protocol dosing, see our VIP dosage calculator →

VIP dosage chart

There is no established FDA-approved dose for VIP. The chart below summarizes dosing patterns drawn from published research protocols and peptide community discussions. It is intended for educational reference only — not as a personal dosing plan or medical recommendation.

Protocol Phase	Dose Range	Route	Frequency	Duration	Use Case
Standard	50 mcg per dose	Intranasal	2 doses daily	4-8 weeks	Common research protocol
Lower-dose exploratory	25 mcg per dose	Intranasal	2 doses daily	4-6 weeks	Conservative start
Higher-dose	100 mcg per dose	Intranasal / SubQ	2 doses daily	4-8 weeks	Upper discussed range
Cycle break	No dose	—	—	2-4 weeks	Recovery period

For dose calculations, reconstitution math, and syringe unit conversions, see our VIP dosage calculator →

How VIP works

VIP

Understanding the pharmacokinetic profile helps explain the dosing patterns. ~1-2 minutes

For quick dose calculations based on these protocols, use our VIP dosage calculator →

Administration routes

VIP is commonly discussed as administered via intranasal or subcutaneous in research literature. The choice of route affects bioavailability, onset, and duration of effect.

For reconstitution math and syringe unit calculations, see our VIP dosage calculator →

Cycle structure and timing

Research protocols for VIP typically follow a cycle structure with distinct phases: loading, maintenance, and recovery. The specific duration of each phase depends on the research context and should be discussed with a qualified professional.

Safety considerations

VIP is not FDA-approved for human use. All dosing information in this guide is presented for educational and research purposes only. Consult a licensed healthcare provider before considering any peptide protocol.

Frequently asked questions

See the FAQ section below for common questions about VIP dosing, administration, and research status.

Related Peptides

Frequently Asked Questions

What is the typical dose of VIP?

Research protocols typically discuss the ranges shown in our VIP dosage chart (2x daily, intranasal or subcutaneous). These ranges are drawn from published research and community discussion, not FDA-approved clinical guidelines. No established therapeutic dose exists for VIP.

How is VIP administered?

VIP is typically discussed as administered via intranasal or subcutaneous in research literature. The specific route depends on the research protocol and should be discussed with a qualified professional.

Is VIP FDA-approved?

No. VIP is not FDA-approved for any therapeutic use. Regulations vary by jurisdiction. All information presented here is for educational and research purposes only.

What is the half-life of VIP?

The half-life of VIP is approximately ~1-2 minutes. This information is based on limited research data and should not be used for personal dosing decisions.

What are the side effects of VIP?

Side effects are compound-specific and not fully characterized in human studies. Potential effects include injection site reactions, mild headache, or transient changes in the target system. Discuss any reactions with a healthcare provider.